The Therapeutic Trials

  • James A. Schoenberger
Part of the Atlas of Heart Diseases book series (AD)


There are two types of therapeutic trials used in the field of hypertension. Most are short-term trials of antihypertensive drugs compared with placebos or other agents, carried out to demonstrate the efficiency and safety of the drug being tested in reducing elevated blood pressure. The trials reviewed in this chapter are of the second type, those that evaluate the long-term benefit of blood pressure reduction in preventing the morbidity and mortality associated with elevated blood pressure. Although fewer in number, these therapeutic trials have established the value of treating hypertension, have defined the level of elevated blood pressure above which treatment is warranted, and have instigated the widespread public health approach to the treatment of hypertension, which is epitomized by the National High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute. Since 1972, the death rates for stroke and coronary heart disease have declined by more than 60% and 40%, respectively. It is reasonable to assume that better identification of persons with elevated blood pressure and more vigorous treatment inspired by these trials have contributed significantly to this result.


Coronary Heart Disease Diastolic Blood Pressure Hypertension Optimal Treatment Hypertension Detection Medical Research Council Working Party 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967, 202: 1028–1034.CrossRefGoogle Scholar
  2. 2.
    Neaton JD, Grumm RH, Prineas RJ, et al.: Treatment of Mild Hypertension Study (TOMHS): final results. JAMA 1993, 270: 713–724.PubMedCrossRefGoogle Scholar
  3. 3.
    The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993, 153: 154–183.Google Scholar
  4. 4.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213: 1143–1252.CrossRefGoogle Scholar
  5. 5.
    Australian National Blood Pressure Management Committee: Treatment of mild hypertension in the elderly. Med J Aust 1981, 2: 398–402.Google Scholar
  6. 6.
    Australian National Blood Pressure Management Committee: The Australian National Therapeutic trial in mild hypertension. Lancet 1980, 1: 1261–1267.Google Scholar
  7. 7.
    Amery A, Burkenhager W, Bixka P, et al.: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985, 1: 1349–1354.PubMedCrossRefGoogle Scholar
  8. 8.
    Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: I. Reductions in mortality in persons with high blood pressure including mild hypertension. JAMA 1979, 242: 2562–2571.CrossRefGoogle Scholar
  9. 9.
    Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race, sex and age. JAMA 1979, 242: 2572–2576.CrossRefGoogle Scholar
  10. 10.
    Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982, 247: 633–638.CrossRefGoogle Scholar
  11. 11.
    Hypertension Detection and Follow-up Program Cooperative Group: Effect of stepped care in the incidence of myocardial infarction and angina pectoris. Hypertension 1984, 6(suppl): 198–206.CrossRefGoogle Scholar
  12. 12.
    Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 1985, 291: 97–104.CrossRefGoogle Scholar
  13. 13.
    Wilhelmsen L, Berglund G, Elmfeldt D, et al.: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens 1987, 5: 561–572.PubMedCrossRefGoogle Scholar
  14. 14.
    Wikstrand J, Warnold I, Olssor G, et al.: Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA 1988, 259: 1976–1982.PubMedCrossRefGoogle Scholar
  15. 15.
    MacMahon S, Peto S, Cutter J, et al.: Blood pressure, stroke and coronary heart disease: Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335: 765–774.PubMedCrossRefGoogle Scholar
  16. 16.
    Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335: 827–838.PubMedCrossRefGoogle Scholar
  17. 17.
    Kaplan N: Changing hypertension treatment to reduce the overall cardiovascular risk. J Hypertens 1990, 8(suppl 7):S175–179.CrossRefGoogle Scholar
  18. 18.
    Dahlof B, Perrnert K, Hannson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5: 95–110.PubMedGoogle Scholar
  19. 19.
    Devereux RB, Agabiti-Rosei E, Dahlof B, et al.: Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996, 14(suppl): 95–101.CrossRefGoogle Scholar
  20. 20.
    McClellan K: Unexpected results from MIDAS in atherosclerosis. Inpharma 1994, 932: 4–8.CrossRefGoogle Scholar
  21. 21.
    Epstein M: Calcium antagonists: still appropriate as first-line antihypertensive agents. Am J Hypertens 1996, 9: 110–121.PubMedCrossRefGoogle Scholar
  22. 22.
    Insua JT, Sacks HS, Lau T, et al.: Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994, 121: 355–362.PubMedGoogle Scholar
  23. 23.
    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255–3264.CrossRefGoogle Scholar
  24. 24.
    Dahlof B, Lindholm L, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338: 1281–1284.PubMedCrossRefGoogle Scholar
  25. 25.
    MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 1304: 405–412.Google Scholar
  26. 26.
    The HOT Study Group: The Hypertension Optimal Treatment (HOT) Study: a prospective study of the optimal therapeutic goal and the value of low-dose aspirin in the antihypertensive. Blood Pressure 1993, 2: 113–119.CrossRefGoogle Scholar
  27. 27.
    Mallion JM, Pehrsson NG, Raveau-Landon C, et al.: Short and long-term clinical tolerance of hypertension treatment during the HOT study (Hypertension Optimal Treatment). Arach Mal Coeur Vaiss 1996, 89: 1093–1096.Google Scholar
  28. 28.
    Kjeldson SE, Syvertsen JO, Lund-Johnasen P: Status of ongoing controlled clinical trials on hypertension. Tidsskr Nor Laegeforen 1996, 116: 61–63.Google Scholar
  29. 29.
    Davis BR, Cutler JA, Gordon DJ, et al.: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996, 9: 342–360.PubMedCrossRefGoogle Scholar
  30. 30.
    Hansson L, Zanchetti S, Carruthers B, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351: 1755–1762.PubMedCrossRefGoogle Scholar
  31. 31.
    Sever PS: Recent clinical trials: a critical appraisal. Curr Hypertension Rep 1999, 1: 333–336.CrossRefGoogle Scholar
  32. 32.
    Bryg RJ, Graettinger WF: The hypertension optimal treatment study: what did it give us? Curr Hypertension Rep 1999, 1: 337–341.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • James A. Schoenberger

There are no affiliations available

Personalised recommendations